Fluciclovine PET/CT
Phase 3Small molecule
Fluciclovine PET/CT is one of 31 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
312 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Acetylsalicylic Acid
BayerPhase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
SHR3680
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Fluciclovine PET/CT
OOHSU Knight Cancer Institute
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluciclovine PET/CT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- OOHSU Knight Cancer Institute